Cyclin-Dependent Kinase 5 (Cdk5) Inhibitory Peptide
Invention type: Technology
/
Case number: #19569P
The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject a specific CDK5 peptide inhibitor and a pharmaceutically acceptable carrier.
Researchers
Li-Huei Tsai
/
Jinsoo Seo
Departments: DLC Heads Science
Technology Areas: Therapeutics: Proteins & Antibodies, Small Molecules
Impact Areas: Healthy Living
-
cyclin-dependent kinase 5 (cdk5) inhibitory peptide
Japan | Published application -
cyclin-dependent kinase 5 (cdk5) inhibitory peptides
Brazil | Published application -
cyclin-dependent kinase 5 (cdk5) inhibitory peptides
Korea (south) | Published application -
cyclin-dependent kinase 5 (cdk5) inhibitory peptides
United States of America | Published application -
cyclin-dependent kinase 5 (cdk5) inhibitory peptide
Canada | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.